Do GLP-1 medicines lower diabetes risk for Black and Latina women?
# Do GLP-1 medicines lower diabetes risk for Black and Latina women?
Black and Latina women carry a heavier burden of type 2 diabetes and obesity than white women in the United States, so the honest question is a practical one: do these medicines meaningfully reduce the odds of developing diabetes, and does the trial evidence actually apply to women who look like you? This piece walks through what the epidemiology shows, what the trials measured, and where the caveats are.
Key takeaways
Dr. Linda's take
The question under this question is usually more personal: my community carries more of this disease, so does the treatment actually help us, and was it even tested on us? Both halves deserve a straight answer.
Here is the honest version. The trial evidence that these medicines can delay or prevent progression to diabetes is genuinely strong, and where researchers checked whether the benefit held across racial and ethnic groups, it did. At the same time, Black and Latina women were under-represented relative to how heavily these conditions fall on their communities, and the barrier for many women is not the science but whether they can get the medicine at all. Holding both of those truths at once is what lets you trust the evidence without being naive about its limits. If you want a sense of whether treatment is even a fit for your situation, our eligibility quiz is one place to start. Everything below is what the data actually shows.
Why are Black and Latina women at higher risk of diabetes?
The starting point is not in dispute. According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than half of non-Hispanic Black women, and more than two in five Hispanic women, have obesity, compared with nearly two in five non-Hispanic white women. The diabetes gap runs alongside it. In national survey data from 2011 to 2016, the age- and sex-adjusted prevalence of total diabetes was 20.4% among non-Hispanic Black adults and 22.1% among Hispanic adults, compared with 12.1% among non-Hispanic white adults.
It matters how we read those numbers. Being overweight or having obesity raises the risk of type 2 diabetes, which is part of why these two health gaps tend to travel together. But the gaps themselves are driven by unequal access to healthy food, safe places to move, time, and care, not by anything essential to race. We cover the fuller picture in why Black and Latina women face higher obesity and diabetes risk.
Do GLP-1 medicines lower the chance of developing diabetes?
This is where the evidence is strongest, and it is worth being precise about what was measured. Many women start this journey with prediabetes. Prediabetes means blood glucose levels that are higher than normal, but not high enough to be diagnosed as type 2 diabetes. It is not harmless: people with prediabetes have a high chance of developing type 2 diabetes within five to ten years. That is exactly the window these trials tested.
In two separate three-year randomized trials, GLP-1 based medicines lowered the chance that people with obesity and prediabetes went on to develop type 2 diabetes, compared with placebo. The numbers are striking. In SURMOUNT-1, a three-year trial in adults with obesity and prediabetes, type 2 diabetes was diagnosed in 1.3% of those on tirzepatide compared with 13.3% of those on placebo. In a separate three-year trial of liraglutide in people with prediabetes, 2% of the liraglutide group versus 6% of the placebo group were diagnosed with diabetes over 160 weeks.
There is an important caveat that keeps this honest. That protection appears to depend on staying on treatment: after just 17 weeks off tirzepatide, type 2 diabetes had been diagnosed in 2.4% of that group versus 13.7% of the placebo group. The gap versus placebo held, which is real good news, but the diagnosis rate in the treated group nearly doubled in only 17 weeks off the medicine. If you want the deeper version of this point, we walk through it in whether these medicines can reverse prediabetes.
Does the trial evidence apply to Black and Latina women?
This is the part I most want women to hear, because it is where researchers did the careful work. A post hoc analysis of three semaglutide trials found no significant interactions between treatment effect and race, and concluded that the treatment effect of semaglutide was statistically significant versus placebo and clinically relevant across all racial and ethnic subgroups studied. In plain terms, the analysis did not find that the medicine worked meaningfully differently from one group to another.
Now the caveat that keeps that honest. In the pooled STEP 1 and STEP 3 semaglutide trials, participants reported their race as White in 75.3%, Black in 8.8%, Asian in 10.6%, or another group in 5.3% of cases, and 13.9% reported Hispanic or Latino ethnicity. The Black subgroup in that analysis was only about 9% of participants, and a subgroup that small has limited power to detect a modest difference if one truly exists. So the reassuring finding is real, and its confidence has limits. Both things are true. We go further into this in whether these medicines work as well for Black and Latina women.
What about actually getting the medicine?
For many women, the science is not the obstacle. Access is. In a retrospective cohort study of more than one million commercially insured US adults with type 2 diabetes, Asian, Black, and Hispanic patients, and those with lower incomes, were less likely to receive a GLP-1 receptor agonist than white and higher-income patients. The authors of that study note that racial and ethnic disparities in health outcomes are largely attributable to the pervasiveness of structural racism, and that patients marginalized by racism have less access to novel therapeutics.
That framing matters. The women who stand to benefit most are, on average, the least likely to be offered treatment, which is a structural problem rather than a personal failing. Knowing that helps you push, respectfully and firmly, for the same options anyone else would be offered.
What should you know before starting?
This is general education, not a recommendation for any one person. But the evidence gives you better questions to bring to a visit:
Frequently asked questions
Do GLP-1 medicines lower the chance of developing diabetes?
In two separate three-year randomized trials, GLP-1 based medicines lowered the chance that people with obesity and prediabetes went on to develop type 2 diabetes, compared with placebo. In SURMOUNT-1, a three-year trial in adults with obesity and prediabetes, type 2 diabetes was diagnosed in 1.3% of those on tirzepatide compared with 13.3% of those on placebo.
Does the benefit last if you stop the medicine?
Not fully, based on what has been measured. That protection appears to depend on staying on treatment: after just 17 weeks off tirzepatide, type 2 diabetes had been diagnosed in 2.4% of that group versus 13.7% of the placebo group. The advantage over placebo held, but diagnoses rose quickly.
Did the medicine work as well for Black and Latina participants?
A post hoc analysis of three semaglutide trials found no significant interactions between treatment effect and race, and concluded that the treatment effect of semaglutide was statistically significant versus placebo and clinically relevant across all racial and ethnic subgroups studied. The Black subgroup in that analysis was only about 9% of participants, and a subgroup that small has limited power to detect a modest difference if one truly exists.
Why do Black and Latina women carry more diabetes risk in the first place?
In national survey data from 2011 to 2016, the age- and sex-adjusted prevalence of total diabetes was 20.4% among non-Hispanic Black adults and 22.1% among Hispanic adults, compared with 12.1% among non-Hispanic white adults. Being overweight or having obesity raises the risk of type 2 diabetes, which is part of why these two health gaps tend to travel together. The gaps reflect unequal conditions and access, not biology.
Is it harder for Black and Latina women to get these medicines?
Often, yes. In a retrospective cohort study of more than one million commercially insured US adults with type 2 diabetes, Asian, Black, and Hispanic patients, and those with lower incomes, were less likely to receive a GLP-1 receptor agonist than white and higher-income patients.
References
1. NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). Overweight & Obesity Statistics. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity (Accessed 2026-07-25).
2. JAMA (2019). Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016. PubMed PMID 31860047. https://pubmed.ncbi.nlm.nih.gov/31860047/ (Accessed 2026-07-25).
3. MedlinePlus. Type 2 Diabetes. https://medlineplus.gov/diabetestype2.html (Accessed 2026-07-25).
4. NIDDK. Prediabetes & Insulin Resistance. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance (Accessed 2026-07-25).
5. The New England Journal of Medicine (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1). PubMed PMID 39536238. https://pubmed.ncbi.nlm.nih.gov/39536238/ (Accessed 2026-07-25).
6. The Lancet (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes. PubMed PMID 28237263. https://pubmed.ncbi.nlm.nih.gov/28237263/ (Accessed 2026-07-25).
7. Obesity (Silver Spring) (2024). Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials. PubMed PMID 38932728. https://pubmed.ncbi.nlm.nih.gov/38932728/ (Accessed 2026-07-25).
8. JAMA Health Forum (2022). Association of Race/Ethnicity, Gender, and Socioeconomic Status With GLP-1 RA and SGLT2 Inhibitor Use. PubMed PMID 35977298. https://pubmed.ncbi.nlm.nih.gov/35977298/ (Accessed 2026-07-25).
---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*
*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-25.*
Keep reading
Can a GLP-1 improve menstrual regularity in women with PCOS?
In PCOS, irregular periods are tied to insulin resistance and weight. Dr. Linda Moleon, MD reviews what the research shows about GLP-1 medicines and menstrual regularity.
Does a GLP-1 reduce visceral fat after menopause?
After menopause, fat shifts to the deep belly. Dr. Linda Moleon, MD reviews what imaging trials show about whether GLP-1 medicines reduce visceral fat, and where the evidence stops.
Does a GLP-1 improve cholesterol during perimenopause?
Cholesterol often drifts upward in perimenopause on its own. Dr. Linda Moleon, MD explains what shifts, what GLP-1 medicines do to lipids, and where the evidence is solid versus extrapolated.
How do you start a GLP-1 in Tampa?
Starting a GLP-1 around Tampa Bay is less about what these medicines are and more about how you actually begin. Dr. Linda Moleon, MD lays out the practical steps.
How do you start a GLP-1 in Orlando?
Starting a GLP-1 in Orlando is less about what these medicines are and more about how you actually begin. Dr. Linda Moleon, MD lays out the practical steps.
Does a GLP-1 affect blood pressure differently in Black women?
Black women carry a heavier hypertension burden, so it is fair to ask how these medicines affect blood pressure. Dr. Linda Moleon, MD on what the data shows and where it is thin.